ECSP23054131A - Cocristal de un inhibidor de cdk - Google Patents
Cocristal de un inhibidor de cdkInfo
- Publication number
- ECSP23054131A ECSP23054131A ECSENADI202354131A ECDI202354131A ECSP23054131A EC SP23054131 A ECSP23054131 A EC SP23054131A EC SENADI202354131 A ECSENADI202354131 A EC SENADI202354131A EC DI202354131 A ECDI202354131 A EC DI202354131A EC SP23054131 A ECSP23054131 A EC SP23054131A
- Authority
- EC
- Ecuador
- Prior art keywords
- cocrystal
- cdk inhibitor
- relates
- cdk7
- disorders
- Prior art date
Links
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 abstract 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- -1 fumarate compound Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202041055174 | 2020-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23054131A true ECSP23054131A (es) | 2023-09-29 |
Family
ID=80001496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202354131A ECSP23054131A (es) | 2020-12-18 | 2023-07-18 | Cocristal de un inhibidor de cdk |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240059669A1 (https=) |
| EP (1) | EP4263534A1 (https=) |
| JP (1) | JP2023554492A (https=) |
| KR (1) | KR20230159363A (https=) |
| CN (1) | CN116685326A (https=) |
| AU (1) | AU2021402415A1 (https=) |
| CA (1) | CA3202198A1 (https=) |
| CL (1) | CL2023001753A1 (https=) |
| CO (1) | CO2023009368A2 (https=) |
| CR (1) | CR20230261A (https=) |
| DO (1) | DOP2023000126A (https=) |
| EC (1) | ECSP23054131A (https=) |
| IL (1) | IL303738A (https=) |
| MX (1) | MX2023007218A (https=) |
| PE (1) | PE20231441A1 (https=) |
| TW (1) | TW202241881A (https=) |
| WO (1) | WO2022130304A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022084930A2 (en) * | 2020-10-22 | 2022-04-28 | Aurigene Discovery Technologies Limited | Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2023224961A1 (en) | 2022-05-16 | 2023-11-23 | Exelixis, Inc. | Cancer therapy using a combination of a cdk7 inhibitor with an oral serd |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN118772106A (zh) * | 2024-06-07 | 2024-10-15 | 山东大学 | 伊马替尼-没食子酸共晶、其溶剂化物、制备方法和应用 |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3302448T1 (sl) | 2015-06-04 | 2024-03-29 | Aurigene Oncology Limited | Substituirani heterociklični derivati kot inhibitorji cdk |
-
2021
- 2021-12-17 PE PE2023001908A patent/PE20231441A1/es unknown
- 2021-12-17 AU AU2021402415A patent/AU2021402415A1/en not_active Abandoned
- 2021-12-17 EP EP21848027.5A patent/EP4263534A1/en active Pending
- 2021-12-17 WO PCT/IB2021/061895 patent/WO2022130304A1/en not_active Ceased
- 2021-12-17 TW TW110147455A patent/TW202241881A/zh unknown
- 2021-12-17 MX MX2023007218A patent/MX2023007218A/es unknown
- 2021-12-17 CN CN202180085401.XA patent/CN116685326A/zh active Pending
- 2021-12-17 CA CA3202198A patent/CA3202198A1/en active Pending
- 2021-12-17 US US18/257,962 patent/US20240059669A1/en active Pending
- 2021-12-17 JP JP2023537470A patent/JP2023554492A/ja active Pending
- 2021-12-17 CR CR20230261A patent/CR20230261A/es unknown
- 2021-12-17 KR KR1020237024297A patent/KR20230159363A/ko active Pending
- 2021-12-17 IL IL303738A patent/IL303738A/en unknown
-
2023
- 2023-06-15 CL CL2023001753A patent/CL2023001753A1/es unknown
- 2023-06-16 DO DO2023000126A patent/DOP2023000126A/es unknown
- 2023-07-14 CO CONC2023/0009368A patent/CO2023009368A2/es unknown
- 2023-07-18 EC ECSENADI202354131A patent/ECSP23054131A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023009368A2 (es) | 2023-09-29 |
| KR20230159363A (ko) | 2023-11-21 |
| EP4263534A1 (en) | 2023-10-25 |
| WO2022130304A1 (en) | 2022-06-23 |
| CN116685326A (zh) | 2023-09-01 |
| MX2023007218A (es) | 2023-07-27 |
| CA3202198A1 (en) | 2022-06-23 |
| JP2023554492A (ja) | 2023-12-27 |
| US20240059669A1 (en) | 2024-02-22 |
| CR20230261A (es) | 2023-10-04 |
| IL303738A (en) | 2023-08-01 |
| TW202241881A (zh) | 2022-11-01 |
| PE20231441A1 (es) | 2023-09-14 |
| DOP2023000126A (es) | 2023-11-30 |
| AU2021402415A1 (en) | 2023-07-06 |
| CL2023001753A1 (es) | 2024-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| CO2024005925A2 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| CO2023013356A2 (es) | Compuestos para la inhibición de nlrp3 y usos de estos | |
| BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
| MX2022010795A (es) | Hidrato cristalino de un compuesto inhibidor de jak. | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| EA201992601A1 (ru) | Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak | |
| NO20076093L (no) | Substituerte amidderivater som proteinkinaseinhibitorer | |
| NO20033181L (no) | Substituerte alkylaminderivater og fremgangsmåter for anvendelse | |
| NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| ZA202007566B (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| CU24671B1 (es) | Compuesto de pirimidina inhibidor de las janocinasas, composición, forma cristalina y proceso de preparación | |
| CL2022001887A1 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| MX2023000521A (es) | Derivados de piridazinil-amino como inhibidores de el receptor tipo i de factor de crecimiento transformante beta (alk5). | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
| BR112022010181A2 (pt) | Composto tri-heterocíclico como inibidor de jak e uso do mesmo | |
| CL2025000672A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer. | |
| JOP20200079A1 (ar) | مثبطات مستقبل عامل نمو البشرة | |
| CL2025000120A1 (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b. | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. |